A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Trial Profile

A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Insulin degludec (Primary)
  • Indications Diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 28 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 20 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top